Tokyo Tape
Sign in
← SymBio Pharmaceuticals

Annual report

4582.TEDINET S100XNE5
Period2025-01-01 → 2025-12-31
Filed2026-03-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 130
MetricValuePeriodScopeSource row
Revenue¥1.3bn2025-01-01 → 2025-12-31Cons.Net sales
Revenue¥2.5bn2024-01-01 → 2024-12-31Cons.Net sales
Revenue¥5.6bn2023-01-01 → 2023-12-31vCons.Net sales (5-year summary)
Revenue¥10.0bn2022-01-01 → 2022-12-31vCons.Net sales (5-year summary)
Operating income−¥4.4bn2025-01-01 → 2025-12-31Cons.Operating income
Operating income−¥3.9bn2024-01-01 → 2024-12-31Cons.Operating income
Ordinary income−¥4.6bn2025-01-01 → 2025-12-31Cons.Ordinary income
Ordinary income−¥3.7bn2024-01-01 → 2024-12-31Cons.Ordinary income
Ordinary income−¥736m2023-01-01 → 2023-12-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥2.0bn2022-01-01 → 2022-12-31vCons.Ordinary income loss (5-year summary)
Profit before tax−¥4.7bn2025-01-01 → 2025-12-31Cons.Income before income taxes
Profit before tax−¥3.8bn2024-01-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)−¥4.8bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.8bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.0bn2023-01-01 → 2023-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.2bn2022-01-01 → 2022-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥4.8bn2025-01-01 → 2025-12-31Cons.Profit loss
Net income−¥3.8bn2024-01-01 → 2024-12-31Cons.Profit loss
Total assets¥3.9bnat 2025-12-31Cons.Assets
Total assets¥5.0bnat 2024-12-31Cons.Assets
Total assets¥8.2bnat 2023-12-31vCons.Total assets (5-year summary)
Total assets¥10.4bnat 2022-12-31vCons.Total assets (5-year summary)
Total liabilities¥2.6bnat 2025-12-31Cons.Liabilities
Total liabilities¥771mat 2024-12-31Cons.Liabilities
Net assets / equity¥1.3bnat 2025-12-31Cons.Net assets
Net assets / equity¥4.2bnat 2024-12-31Cons.Net assets
Net assets / equity¥7.2bnat 2023-12-31vCons.Net assets
Net assets / equity¥8.5bnat 2022-12-31vCons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2025-12-31Cons.Cash and deposits
Cash and deposits¥4.0bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.0bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥6.5bnat 2023-12-31vCons.Cash and cash equivalents
Cash & equivalents¥6.3bnat 2022-12-31vCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥4.6bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥3.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥195m2023-01-01 → 2023-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.6bn2022-01-01 → 2022-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥76m2025-01-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥4m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥377m2023-01-01 → 2023-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥47m2022-01-01 → 2022-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥3.6bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥708m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥680m2023-01-01 → 2023-12-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥628m2022-01-01 → 2022-12-31vCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-95.122025-01-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-852024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-49.192023-01-01 → 2023-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.22022-01-01 → 2022-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥29.772022-01-01 → 2022-12-31vCons.Diluted earnings per share (5-year summary)
Net assets per share¥15.54at 2025-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥84.66at 2024-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥164.32at 2023-12-31vCons.Net assets per share (5-year summary)
Net assets per share¥204.83at 2022-12-31vCons.Net assets per share (5-year summary)
Equity ratio23.9%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio78.1%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio84.9%at 2023-12-31vCons.Equity to asset ratio (5-year summary)
Equity ratio77.6%at 2022-12-31vCons.Equity to asset ratio (5-year summary)
ROE14.6%2022-01-01 → 2022-12-31vCons.Rate of return on equity (5-year summary)
Employees91at 2025-12-31Cons.Number of employees
Employees108at 2024-12-31Cons.Number of employees
Employees109at 2023-12-31vCons.Number of employees
Employees122at 2022-12-31vCons.Number of employees
Revenue¥1.3bn2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥2.5bn2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥5.6bn2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥10.0bn2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥8.3bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥4.6bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥4.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥4.8bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥3.8bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥774m2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.0bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.0bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥4.9bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥3.9bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥4.9bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥3.9bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥2.0bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income¥2.0bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.6bnat 2025-12-31StandaloneAssets
Total assets¥4.7bnat 2024-12-31StandaloneAssets
Total assets¥8.2bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥10.4bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥8.5bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥2.5bnat 2025-12-31StandaloneLiabilities
Total liabilities¥639mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.0bnat 2025-12-31StandaloneNet assets
Net assets / equity¥4.1bnat 2024-12-31StandaloneNet assets
Net assets / equity¥7.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥8.5bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥6.7bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.5bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥3.7bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥3.9bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥140m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥71m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥72m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-97.622025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-872024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-49.792023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥30.372022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥53.042021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥29.952022-01-01 → 2022-12-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.322021-01-01 → 2021-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥11.38at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥82.12at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥164.02at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥204.95at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥162.26at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio19.0%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.7%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio77.8%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio73.7%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE16.6%2022-01-01 → 2022-12-31vStandaloneRate of return on equity (5-year summary)
ROE39.6%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued59,567,080at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued45,928,856at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued42,278,081at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued39,603,606at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued38,457,206at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees86at 2025-12-31StandaloneNumber of employees
Employees101at 2024-12-31StandaloneNumber of employees
Employees103at 2023-12-31vStandaloneNumber of employees
Employees118at 2022-12-31vStandaloneNumber of employees
Employees141at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Research And Development Manufacturing And Sales Of Pharmaceuticals Etc And Related Businessreportable segmentemployeesat 2025-12-3191 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,228
ItemContextValueUnit
Net assetsCurrentYearInstant_NonConsolidatedMember_RetainedEarningsMember-37696551000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-89870000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember_ShareholdersEquityMember3764020000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember316758000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember4080779000JPY
Issuance of new sharesCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Issuance of new sharesCurrentYearDuration_NonConsolidatedMember－JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember1314573000JPY
Issuance of new sharesexercise of subscription rights to sharesCurrentYearDuration_NonConsolidatedMember1314573000JPY
Conversion of convertible bond ssCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember500000000JPY
Conversion of convertible bond ssCurrentYearDuration_NonConsolidatedMember500000000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-4901880000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember-4901880000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-49000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember-49000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember7000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember7000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember31110000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember31110000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-3087348000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember31110000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-3056237000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember676671000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember347869000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember1024541000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember151750000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember165457000JPY
Payroll and allowances sgaPrior1YearDuration_NonConsolidatedMember466873000JPY
Payroll and allowances sgaCurrentYearDuration_NonConsolidatedMember482333000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember1346000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember573000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember3482414000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember3437723000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember112218000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember60502000JPY
Promotion expenses sgaPrior1YearDuration_NonConsolidatedMember692838000JPY
Promotion expenses sgaCurrentYearDuration_NonConsolidatedMember540646000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-03-24
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第21期 (自 2025年１月１日 至 2025年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)シンバイオ製薬株式会社
Company name in english cover pageFilingDateInstantSymBio Pharmaceuticals Limited
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO 吉田 文紀
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant03(5472)1125
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)財務経理部長 　増田　圭吾
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant03(5472)1125

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
balance sheet identitynon_consolidated 2025-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass